<DOC>
	<DOCNO>NCT01133522</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple dose evolocumab give add-on stable statin therapy .</brief_summary>
	<brief_title>Ascending Multiple Dose Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Evolocumab ( AMG 145 ) Adults With Hyperlipidemia Stable Doses Statin</brief_title>
	<detailed_description>Participants receive low-to-moderate-dose statin randomize 1:3 ratio receive subcutaneous placebo evolocumab enrol sequentially one 5 dose-escalation cohort : 1 . Evolocumab 14 mg/placebo weekly ( QW ) × 6 dos 2 . Evolocumab 35 mg/placebo weekly ( QW ) × 6 dos 3 . Evolocumab 140 mg/placebo every 2 week ( Q2W ) × 3 dos 4 . Evolocumab 280 mg/placebo every 2 week ( Q2W ) × 3 dos 5 . Evolocumab 420 mg/placebo every 4 week ( Q2W ) × 2 dos . Participants receive high-dose statin randomize 1:3 receive subcutaneous placebo evolocumab 140 mg every 2 week × 3 dos ( Cohort 6 ) . Participants diagnose familial hypercholesterolemia ( HeFH ) randomize 1:2 receive subcutaneous placebo evolocumab 140 mg every 2 week × 3 dos ( Cohort 7 ) .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Men woman age 18 70 year ( inclusive ) time screen hyperlipidemia Body mass index ( BMI ) ≥18 ≤ 35 kg/m^2 time screen Lowdensity lipoprotein cholesterol ( LDLC ) level 70220 mg/dL ( inclusive ) screening measure direct assay For Cohorts 15 : On stable dose rosuvastatin ( Crestor ) &lt; 40 mg/day , atorvastatin ( Lipitor ) &lt; 80 mg/day , simvastatin ( Zocor ) 2080 mg/day ≥ 1 month prior enrollment expect remain dose remainder study For Cohort 6 : On stable dose rosuvastatin ( Crestor ) 40 mg/day atorvastatin ( Lipitor ) 80 mg/day ≥ 1 month prior enrollment expect remain dose remainder study For Cohort 7 : Diagnosis heterozygous familial hypercholesterolemia , base score ≥ 9 point use World health Organization ( WHO ) criteria Diagnosis homozygous familial hypercholesterolemia History heart failure , coronary artery bypass graft , cardiac arrhythmia History acute coronary syndrome ( e.g . myocardial infarction , hospitalization unstable angina ) percutaneous coronary intervention , within 12 month prior enrollment Planned cardiac surgery revascularization Known aortic , peripheral vascular cerebrovascular disease ( include history stroke transient ischemic attack ) Diabetes mellitus following : 1. know microvascular macrovascular disease 2 . HbA1c &gt; 8.0 % screen 3. use hypoglycemic medication metformin Uncontrolled hypertension ( systolic blood pressure ≥ 150 diastolic blood pressure ≥ 90 mmHg ) either therapy screening baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>AMG145</keyword>
	<keyword>Multiple Dose</keyword>
	<keyword>Statin</keyword>
	<keyword>Ascending</keyword>
</DOC>